QR kód

Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan

Abstract Purpose Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC). Thus, we aimed to find the optimal management for PDAC patients with a history of ILD induced by a gemcitabine-based regimen. Me...

Celý popis

Uloženo v:
Hlavní autoři: Hiroki Irie, Rei Suzuki, Yoshinori Okubo, Hiroyuki Asama, Naoki Konno, Yuki Noguchi, Ko Watanabe, Goro Shibukawa, Hidemichi Imamura, Tadayuki Takagi, Mitsuru Sugimoto, Yuki Sato, Jun Nakamura, Tsunetaka Kato, Minami Hashimoto, Takumi Yanagita, Takuto Hikichi, Hiromasa Ohira
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2023-04-01
Edice:BMC Cancer
Témata:
Pancreatic ductal adenocarcinoma
Chemotherapy
Gemcitabine
Nab-paclitaxel
Interstitial lung disease
On-line přístup:https://doi.org/10.1186/s12885-023-10781-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky